Topical glycopyrronium tosylate (DRM04) for the treatment of primary axillary hyperhidrosis: Pooled results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials

Introduction: The impact of hyperhidrosis on quality of life is comparable to, or greater than, psoriasis or eczema. Glycopyrronium tosylate (GT; formerly DRM04) is a cholinergic receptor antagonist developed for topical application for the treatment of primary axillary hyperhidrosis. ATMOS-1 (NCT02530281) and ATMOS-2 (NCT02530294) were designed to assess the efficacy and safety of GT in patients with primary axillary hyperhidrosis.